866-997-4948(US-Canada Toll Free)

Thromboembolism-Pipeline Review, H2 2019

Published By :

Global Markets Direct

Published Date : Aug 2019

Category :

Pharmaceutical

No. of Pages : 111 Pages

Thromboembolism - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2019, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 3, 8, 3, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thromboembolism - Overview
Thromboembolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thromboembolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thromboembolism - Companies Involved in Therapeutics Development
Accu-Break Pharmaceuticals Inc
Bayer AG
Bristol-Myers Squibb Co
China Biologic Products Holdings Inc
CSPC Pharmaceutical Group Ltd
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
GC Pharma
Ionis Pharmaceuticals Inc
Laboratorios Farmaceuticos Rovi SA
Ono Pharmaceutical Co Ltd
Portola Pharmaceuticals Inc
Tasly Pharmaceutical Group Co Ltd
Tetherex Pharmaceuticals Corp
Verseon Corp
Thromboembolism - Drug Profiles
antithrombin III (human) - Drug Profile
betrixaban - Drug Profile
BMS-986177 - Drug Profile
Drugs for Pulmonary Embolism - Drug Profile
DS-1040 - Drug Profile
edoxaban tosylate - Drug Profile
enoxaparin sodium - Drug Profile
GC-2107 - Drug Profile
IONIS-FXIRx - Drug Profile
Lysimab - Drug Profile
ONO-7684 - Drug Profile
osocimab - Drug Profile
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Recombinant Protein for Thromboembolism - Drug Profile
rivaroxaban - Drug Profile
SelK-2 - Drug Profile
SYHA-136 - Drug Profile
TAP-ANV - Drug Profile
tecarfarin sodium - Drug Profile
TRX-1 - Drug Profile
urokinase - Drug Profile
VE-1902 - Drug Profile
VE-2851 - Drug Profile
warfarin potassium - Drug Profile
YG-001 - Drug Profile
Zifa-01 - Drug Profile
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Thromboembolism, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Thromboembolism - Pipeline by Accu-Break Pharmaceuticals Inc, H2 2019
Thromboembolism - Pipeline by Bayer AG, H2 2019
Thromboembolism - Pipeline by Bristol-Myers Squibb Co, H2 2019
Thromboembolism - Pipeline by China Biologic Products Holdings Inc, H2 2019
Thromboembolism - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019
Thromboembolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Thromboembolism - Pipeline by GC Pharma, H2 2019
Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Thromboembolism - Pipeline by Laboratorios Farmaceuticos Rovi SA, H2 2019
Thromboembolism - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H2 2019
Thromboembolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2019
Thromboembolism - Pipeline by Tetherex Pharmaceuticals Corp, H2 2019
Thromboembolism - Pipeline by Verseon Corp, H2 2019
Thromboembolism - Dormant Projects, H2 2019
Thromboembolism - Dormant Projects, H2 2019 (Contd..1), H2 2019
Thromboembolism - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Thromboembolism, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *